Mylan earnings hit on EMEA growth, while Shire misses; Research probe into Novartis' Diovan broadens;

@FiercePharma: Regeneron, Eylea now 7 for 7 in beating Wall Street forecasts. More | Follow @FiercePharma

@EricPFierce: GSK secretly monitored chat boards for parent discussions on vaccinations. Report | Follow @EricPFierce

> Generic drugmaker Mylan ($MYL) beat Wall Street projections in the first quarter but had to rely on higher sales in the EMEA region to offset a 5% hit to revenues in the U.S. Story

> Shire's ($SHPG) new CEO Flemming Ornskov said he would flatten out the management structure at the company after the first quarterly earning report he presided over turned in disappointing results. Story

> The biotech stock manipulator David Blech received a four-year prison sentence after pleading guilty a second time to improper trading. Story

> A new report from the Substance Abuse and Mental Health Services Administration found a 220% jump between 2005 and 2010 in emergency room visits from adverse reactions to the sleep drug zolpidem, the API in Ambien, reaching nearly 20,000 in 2010. Story

> Novartis ($NVS) has opened an investigation after learning that a company employee was affiliated with a study of its blood pressure drug Diovan as a statistician without revealing his ties to the Swiss healthcare giant. Report

> Regulators in Canada have issued a warning after hearing from Roche ($RHHBY) that its cancer drug Avastin has been tied to 52 cases of the so-called flesh-eating virus necrotizing fasciitis, including two in Canada and one there that resulted in death. Story

Medical Device News

@FierceMedDev: Implant successfully predicts human epilepsy seizures. Item | Follow @FierceMedDev

@MarkHFierce: A Dx to predict prostate cancer recurrence produced some hopeful early results. DxExtra | Follow @MarkHFierce

 @DamianFierce: Life Tech posts tepid quarterly results as Thermo waits with $13.6B. News | Follow @DamianFierce

> Medtronic lops off 230 spinal jobs, endures FDA blemish. Story

> Zimmer grabs PA startup for cutting-edge knee treatment. Article

> FDA panel rips Delcath drug/device cancer treatment. News

Biotech News

@FierceBiotech: Industry Voices: Who will figure out how to make a business out of fecal transplants? Feature | Follow @FierceBiotech

@JohnCFierce: Bristol-Myers' "smart bomb" deal pushes Ambrx 12-month deal tally to $715M. More | Follow @JohnCFierce

@RyanMFierce: Sanofi lets go of rights to Regeneron's antibodies in ophthalmology in $65M agreement. Article | Follow @RyanMFierce

> AltheRx Pharma adds $15M, new CEO and ex-AstraZeneca exec. Article

> Biotech financier Blech gets jail time in 'No mercy' sentence. Report

> Arena shares sink after biotech withdraws marketing app for obesity drug in Europe. News

And Finally... FDA officials last week had to participate in BIO via Skype after tightening budgets due to sequestration kept them from flying to Chicago. Report

Suggested Articles

Late-stage ovarian cancer patients have few options, but now the FDA is reviewing GSK's Zejula for the patient group.

The FDA has raised questions about the manufacturing of Glenmark's new molecular entity Ryaltris, a nasal spray for seasonal allergic rhinitis.

Despite unconventional support from President Donald Trump, Johnson & Johnson’s Spravato didn’t win broad backing at the VA.